MedTrace Logo

Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy

NCT06850454 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2025-02-27

No results posted yet for this study

Summary

A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy

Conditions

  • Chemotherapy Induced Nausea and Vomiting

Interventions

DRUG

olanzapine

olanzapine 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4

DRUG

Placebo

placebo 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2026-01-10
Completion
2026-01-31
FDA Drug
Yes

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06850454 on ClinicalTrials.gov